CONDIVIDIAMO: COVID-19 and Disease Progression to the Severe Form: A Study on the Use of Monoclonal Antibodies Against SARS-CoV-2
Study Details
Study Description
Brief Summary
This is a national multicentre observational study with retrospective and prospective data collection to assess the time to hospitalisation of patients with a confirmed diagnosis of SARS-CoV-2 infection receiving treatment with anti-SARS-CoV-2 monoclonal antibodies.
The subjects enrolled will be patients with early infection of SARS-CoV-2, paucisymptomatic, with risk factors for evolution to the severe form (according to AIFA criteria). Also, hospitalised subjects will be enrolled to receive SARS-CoV-2 monoclonal antibodies because of negative serology (according to AIFA criteria).
It is estimated to enrol about 1000 subjects.
Patients will be evaluated at enrollment and 28 days following administration to collect data on symptoms, possible hospitalization and final clinical outcome (alive with symptoms, alive without symptoms, alive with symptoms and hospitalized or deceased).
Data will be collected using a dedicated electronic Case Report Form (eCRF).
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
|
Study Design
Outcome Measures
Primary Outcome Measures
- Estimating the time to hospitalisation of patients with a confirmed diagnosis of SARS-CoV-2 infection receiving treatment with anti-SARS-CoV-2 monoclonal antibodies up to 30 days [0-30 days]
Secondary Outcome Measures
- Estimating the COVID-19 lethality rate in patients receiving monoclonal antibodies (mAb) at 30 days. [0-30 days]
- Describing the evolution of COVID-19 symptoms in patients receiving mAb up to 30 days [0-30 days]
- Identifying possible predictive factors of hospitalisation [0-30 days]
- Describing the clinical progression of patients receiving casirivimab/imdevimab while hospitalized up to 30 days [0-30 days]
Eligibility Criteria
Criteria
Inclusion Criteria:
-
/= 18 years
-
Confirmed diagnosis of SARS-CoV-2 infection
-
Having received or receiving any anti-SARS-CoV-2 monoclonal antibody (or combination of monoclonal antibodies) prescribed through the AIFA registry
-
Signature of informed consent (for subjects enrolled in the prospective part)
Exclusion Criteria:
-
Absence of criteria for prescribing monoclonal antibodies as determined by AIFA
-
Patients already hospitalised for non-COVID reason at the time of monoclonal antibody administration
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Asst-Monza Ospedale San Gerardo | Monza | Lombardia | Italy | 20900 |
Sponsors and Collaborators
- University of Milano Bicocca
Investigators
- Principal Investigator: Paolo Bonfanti, MD, Asst-Monza Ospedale San Gerardo
Study Documents (Full-Text)
None provided.More Information
Publications
None provided.- MABCOVID01